| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_09285a2ed04658703b139c64090f3ab6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate |
1991-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_247fcf2f9766ff39672a08309b850c67
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5cf5382a997ccbefc11882b990082429
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94ccbff02c20438163039e7bfa15cfea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aaced6ba6beec5d621ed4ad31ae4d167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c72ad4d096d60897a0a115bf9fb99879
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b8f38e00f535524d108e7d14cb5c509
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40ddff79708c55c40bf0c326e7d898d0 |
| publicationDate |
1992-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2086248-A1 |
| titleOfInvention |
Human meg-csf protein and methods |
| abstract |
An isolated human megakaryocyte-colony stimulating factor (hMeg-CSF protein) preferably purified to homogeneity from urine of aplastic anemia patients is disclosed. The novel hMeg-CSF protein is a basic protein having a pI equal to about 7.2-7.4 as determined by isoelectric focusing and a molecular weight of about 29.000-34.000 daltons as determined by SDS-PAGE when in a glycosylated and sialyated form. The novel hMeg-CSF protein has the ability to induce the formation megakaryocyte-colony forming units in a murine fibrin clot assay in vitro, and the further ability to regulate megakaryocytopoiesis and platelet production in vivo. The hMeg-CSF protein can be further characterized as a glycoprotein having biantennary carbohydrate structures, beta-galactose residues as terminal or penultimate sugars and sialic acid moieties. The hMeg-CSF protein is believed to have a specific activity of at least about 4.000 CFU-Meg colonies/mg protein in murine fibrin clot assay. Unique pharmaceuticals containing the hMeg-CSF protein for treating animals including humans and methods for isolating the novel hMeg-CSF protein at various levels of purity are also disclosed. |
| priorityDate |
1990-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |